Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation (OCTET-CY)
This study is currently recruiting participants.
Verified March 2011 by University of Cologne
Sponsor:
University of Cologne
Information provided by:
University of Cologne
ClinicalTrials.gov Identifier:
NCT01283776
First received: January 25, 2011
Last updated: March 15, 2011
Last verified: March 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and to describe the influence of the modified immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution and chimerism.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma Non-Hodgkin-Lymphoma Hodgkin's Disease |
Drug: Cyclophosphamide |
Phase 2 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
Official Title: | A Phase II Study to Investigate the Efficacy of Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation |
Resource links provided by NLM:
Further study details as provided by University of Cologne:
Primary Outcome Measures:
- Number of patients not requiring additional immunosuppression [ Time Frame: day 100 after transplant ] [ Designated as safety issue: Yes ]The primary endpoint is met if at least 1 of the 5 first patients and 3 of a total of 11 patient will reach day 100 after transplant without additional immunsuppressive drug treatment
Secondary Outcome Measures:
- Overall Survival [ Time Frame: day 100 after transplant ] [ Designated as safety issue: Yes ]
- engraftment [ Time Frame: day 100 after transplant ] [ Designated as safety issue: Yes ]absolute neutrophil count of > 0.5 x 10e9/l on 3 consecutive days
- chimerism [ Time Frame: day 100 after transplant ] [ Designated as safety issue: Yes ]Percentage of donor cells in leukocytes from peripheral blood or bone marrow
- relapse incidence [ Time Frame: day 100 after transplant ] [ Designated as safety issue: No ]cumulative incidence of relapse until day 100
- acute GvHD [ Time Frame: day 100 after transplant ] [ Designated as safety issue: Yes ]cumulative incidence of acute GvHD
- non-relapse mortality [ Time Frame: day 100 after transplant ] [ Designated as safety issue: Yes ]cumulative incidence of death from any cause without prior relapse or progression of malignant disease
- immune reconstitution [ Time Frame: day 100 after transplant ] [ Designated as safety issue: No ]relative and absolute counts of B- and T-lymphocyte subsets in peripheral blood
Estimated Enrollment: | 11 |
Study Start Date: | March 2011 |
Estimated Study Completion Date: | February 2012 |
Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: treatment arm
Cyclophosphamide
|
Drug: Cyclophosphamide
100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
|
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Patients with multiple myeloma, Non-Hodgkin's lymphoma or Hodgkin's disease after allogeneic stem cell transplantation with reduced intensity conditioning
- Written informed consent
- No uncontrolled infections
Exclusion Criteria:
- Severe organ dysfunction defined as:
- Cardiac left ventricular ejection fraction (LVEF) of less than 35%
- diffusing lung capacity (DLCO) of less than 40%
- total lung capacity (TLC) of less than 40%
- forced expiratory volume (FEV1) of less than 40%
- total bilirubin >3mg/dl
- creatinine-clearance of less than 40 ml/min
- pregnancy or breast feeding
- participation in other experimental drug trials
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01283776
Contacts
Contact: Christoph Scheid, MD PhD | 49221478 ext 6296 | c.scheid@uni-koeln.de |
Locations
Germany | |
University of Cologne | Recruiting |
Cologne, Germany, 50924 | |
Contact: Christoph Scheid, MD PhD 49221478 ext 6296 c.scheid@uni-koeln.de | |
Sub-Investigator: Udo Holtick, MD |
Sponsors and Collaborators
University of Cologne
Investigators
Principal Investigator: | Christoph Scheid, MD PhD | University of Cologne |
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 26, 2012
No publications provided
Responsible Party: | Christoph Scheid, Principal Investigator, University of Cologne |
ClinicalTrials.gov Identifier: | NCT01283776 History of Changes |
Other Study ID Numbers: | Uni-Koeln-1430 |
Study First Received: | January 25, 2011 |
Last Updated: | March 15, 2011 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Additional relevant MeSH terms:
Hodgkin Disease Lymphoma Lymphoma, Non-Hodgkin Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias |
Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Cyclophosphamide Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Antirheumatic Agents Therapeutic Uses Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists |
ClinicalTrials.gov processed this record on September 26, 2012